(Q51047035)

27 March 2018

title

Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. (English)

1 reference

27 March 2018

author name string

Pierre Burbaud

1

1 reference

27 March 2018

Camille Ducerf

2

1 reference

27 March 2018

Emmanuelle Cugy

3

1 reference

27 March 2018

Jean-Louis Dubos

4

1 reference

27 March 2018

François Muller

5

1 reference

27 March 2018

Dominique Guehl

6

1 reference

27 March 2018

Patrick Dehail

7

1 reference

27 March 2018

Didier Cugy

8

1 reference

27 March 2018

Nicholas Moore

9

1 reference

27 March 2018

Alain Lagueny

10

1 reference

27 March 2018

Pierre-Alain Joseph

11

1 reference

27 March 2018

publication date

20 March 2011

1 reference

27 March 2018

published in

Journal of Neurology

1 reference

27 March 2018

volume

258

1 reference

27 March 2018

issue

9

1 reference

27 March 2018

page(s)

1670-1675

1 reference

27 March 2018

https://scigraph.springernature.com/pub.10.1007/s00415-011-5998-9

exact match

0 references

cites work

A pharmacoeconomic evaluation of botulinum toxin in the treatment of spasmodic torticollis.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-5998-9

Costs of treating dystonias and hemifacial spasm with botulinum toxin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-5998-9

Measuring patient benefit from botulinum toxin in the treatment of dystonia. Feasibility of cost-utility analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-5998-9

Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-5998-9

The Canadian multicentre study of deep brain stimulation for cervical dystonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-5998-9

Costs and efficacy of type A botulinum toxin for the treatment of essential blepharospasm and hemifacial spasm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-5998-9

Pallidal stimulation in cervical dystonia: clinical implications of acute changes in stimulation parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-5998-9

Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-5998-9

Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-5998-9

Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-5998-9

Drug treatments for spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-5998-9

Botulinum toxin type A in post-stroke upper limb spasticity

21 January 2018

1 reference

12 December 2020

Costs and consequences of botulinum toxin type A use. Management of children with cerebral palsy in Germany

1 reference

12 December 2020

[Neurosurgical treatment of primary hemifacial spasm with microvascular decompression]

1 reference

12 December 2020

Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization

1 reference

12 December 2020

Cost impact of botulinum toxin use in Medicaid-enrolled children with cerebral palsy

1 reference

12 December 2020

Botulinum toxin type A therapy for hemifacial spasm

1 reference

12 December 2020

Botulinum toxin type A therapy for cervical dystonia

1 reference

12 December 2020

Facial nerve decompression for idiopathic Bell's palsy: report of 13 cases and literature review

1 reference

12 December 2020

Botulinum toxin type A therapy for blepharospasm

1 reference

12 December 2020

Effects of botulinum toxin-A on gait velocity, step length, and base of support of patients with dynamic equinovarus foot

1 reference

12 December 2020

Pharmacology and upper limb poststroke spasticity: a review. International Society of Prosthetics and Orthotics

1 reference

12 December 2020

Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity

1 reference

12 December 2020

10.1007/S00415-011-5998-9

Identifiers

DOI

1 reference

27 March 2018

release_37grzzpmardcznrgp4dzjxzeim

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/37grzzpmardcznrgp4dzjxzeim

24 November 2022

mapped directly with Wikidata item

1 reference

27 March 2018